.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Citi
Daiichi Sankyo
Deloitte
Cipla
Novartis
McKesson
Colorcon
Merck
Baxter

Generated: November 21, 2017

DrugPatentWatch Database Preview

Mallinkrodt Nuclear Company Profile

« Back to Dashboard

What is the competitive landscape for MALLINKRODT NUCLEAR, and when can generic versions of MALLINKRODT NUCLEAR drugs launch?

MALLINKRODT NUCLEAR has eighteen approved drugs.

There is one US patent protecting MALLINKRODT NUCLEAR drugs.

There are twelve patent family members on MALLINKRODT NUCLEAR drugs in eight countries and thirty supplementary protection certificates in eight countries.

Summary for Mallinkrodt Nuclear

International Patents:12
US Patents:1
Tradenames:15
Ingredients:15
NDAs:18
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinkrodt Nuclear
PHOSPHOCOL P32
chromic phosphate p-32
INJECTABLE;INJECTION017084-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
SODIUM IODIDE I 131
sodium iodide i-131
CAPSULE;ORAL016517-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
SODIUM CHROMATE CR 51
sodium chromate cr-51
INJECTABLE;INJECTION016708-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
SODIUM IODIDE I 131
sodium iodide i-131
CAPSULE;ORAL016517-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
THALLOUS CHLORIDE TL 201
thallous chloride tl-201
INJECTABLE;INJECTION018150-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
SODIUM IODIDE I 131
sodium iodide i-131
CAPSULE;ORAL016515-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
INDIUM IN 111 CHLORIDE
indium in-111 chloride
INJECTABLE;INJECTION019841-001Sep 27, 1994RXYesYes► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
XENON XE 133
xenon xe-133
GAS;INHALATION018327-001Mar 9, 1982RXNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
ULTRA-TECHNEKOW FM
technetium tc-99m sodium pertechnetate generator
SOLUTION;INTRAVENOUS017243-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNETIUM TC-99M SESTAMIBI
technetium tc-99m sestamibi kit
INJECTABLE;INJECTION078098-001Sep 22, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Mallinkrodt Nuclear

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN
technetium tc-99m oxidronate kit
INJECTABLE;INJECTION018321-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN MAG3
technetium tc-99m mertiatide kit
INJECTABLE;INJECTION019882-001Jun 15, 1990► Subscribe► Subscribe
Mallinkrodt Nuclear
ULTRATAG
technetium tc-99m red blood cell kit
INJECTABLE;INJECTION019981-001Jun 10, 1991► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN
technetium tc-99m oxidronate kit
INJECTABLE;INJECTION018321-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Mallinkrodt Nuclear Drugs

Country Document Number Estimated Expiration
Germany4104308► Subscribe
United Kingdom2241167► Subscribe
Belgium1004645► Subscribe
Italy1244496► Subscribe
Hong Kong43497► Subscribe
Japan3288055► Subscribe
United Kingdom9103344► Subscribe
France2658421► Subscribe
JapanH05124979► Subscribe
ItalyRM910115► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Mallinkrodt Nuclear Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
15/009Ireland► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
C0076France► SubscribePRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140514
14/058Ireland► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
595Luxembourg► SubscribePRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Daiichi Sankyo
Mallinckrodt
Boehringer Ingelheim
Queensland Health
Argus Health
Accenture
Cerilliant
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot